Artepharm Global Corp. is committed to participating in the global eradication of malaria through the implementation of ACT (Artemisinin-based Combination Therapy). To date, Artepharm Global Corp.'s artemisinin-based combination, Artequick is a new anti-malarial drug currently available. The FEMSE project was successfully implemented with Artequick, enabling China help fight malaria in Africa. This has laid the foundation for Artequick’s future. Combining Artepharm Co.'s fourth generation of artemisinin-based Artequick with FEMSE and its advanced method of eradicating malaria, Artepharm Global Corp. has the total solution for both the public and private market sectors for fighting malaria worldwide.
Using the FEMSE program, Prof. Li Guoqiao has achieved remarkable results eradicating the source of malaria in pilot projects conducted in Ishii Province and Hong Bu Province in Cambodia. These endemic areas of Cambodia had more than 40 thousand people suffering from malaria. In only one year, the FEMSE project reduced the malaria parasite rate by 94.5%, resulting in no malaria deaths being reported. Over the subsequent two years, these results were consolidated. This program was monitored by the World Health Organization.
In November 2007, after learning about the successful Cambodian three-year pilot
projects, the Comoros Government invited the Artepharm Co. team to implement a FEMSE
program on the Comoros island of Moheli in East Africa. Four months after the project
was started, the plasmodium parasite rate declined by 98%, and the rate of mosquito-borne
malaria parasite positives dropped to zero. One month after the project was started,
the island’s malaria mortality rate dropped rapidly to zero. Over the subsequent year
there were no deaths due to malaria. The project received considerable publicity and
both positive and negative interest around the world.
VIEW DATELINE VIDEO